ELVN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $44,638,962.37

Enliven Therapeutics Insider Trading History Chart

Enliven Therapeutics Share Price & Price History

^$24.41

▼ -0.51 (-2.05%)

As of 11/15/2024 01:00 AM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Enliven Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2024	Benjamin Hohl	CFO	Sell	6,250	$28.56	$178,500.00
10/18/2024	Anish Patel	COO	Sell	716	$30.00	$21,480.00	343,311
10/18/2024	Benjamin Hohl	CFO	Sell	814	$30.00	$24,420.00
10/18/2024	Joseph P Lyssikatos	Insider	Sell	847	$30.00	$25,410.00	1,015,188
10/18/2024	Richard A Heyman	Director	Sell	817	$30.00	$24,510.00	123,673
10/18/2024	Samuel Kintz	CEO	Sell	924	$30.00	$27,720.00	1,002,892
10/15/2024	Richard A Heyman	Director	Sell	1,270	$27.67	$35,140.90	124,490
10/9/2024	Joseph P Lyssikatos	Insider	Sell	37,878	$28.16	$1,066,644.48	1,016,035
10/9/2024	Samuel Kintz	CEO	Sell	16,710	$28.15	$470,386.50	1,003,816
10/8/2024	Rahul D Ballal	Director	Sell	10,420	$28.17	$293,531.40	22,341
10/7/2024	Benjamin Hohl	CFO	Sell	1,270	$27.51	$34,937.70
10/7/2024	Joseph P Lyssikatos	Insider	Sell	2,707	$27.61	$74,740.27	1,067,180
10/7/2024	Samuel Kintz	CEO	Sell	2,730	$27.50	$75,075.00	1,033,793
10/4/2024	Benjamin Hohl	CFO	Sell	10,218	$27.51	$281,097.18
10/4/2024	Joseph P Lyssikatos	Insider	Sell	7,522	$27.51	$206,930.22	1,069,887
10/4/2024	Richard A Heyman	Director	Sell	2,825	$27.51	$77,715.75	125,760
10/4/2024	Samuel Kintz	CEO	Sell	12,206	$27.51	$335,787.06	1,036,523
10/1/2024	Joseph P Lyssikatos	Insider	Sell	527	$27.54	$14,513.58	1,077,409
10/1/2024	Richard A Heyman	Director	Sell	518	$27.54	$14,265.72	128,585
10/1/2024	Samuel Kintz	CEO	Sell	526	$27.54	$14,486.04	1,048,729
9/30/2024	Benjamin Hohl	CFO	Sell	2,000	$25.33	$50,660.00
9/27/2024	Benjamin Hohl	CFO	Sell	4,250	$24.27	$103,147.50
8/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$22.49	$269,880.00	1,077,936
8/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.54	$95,795.00
8/26/2024	Samuel Kintz	CEO	Sell	12,000	$22.89	$274,680.00	1,049,255
8/15/2024	Richard A Heyman	Director	Sell	1,270	$23.25	$29,527.50	130,373
7/31/2024	Benjamin Hohl	CFO	Sell	991	$27.53	$27,282.23
7/31/2024	Joseph P Lyssikatos	Insider	Sell	3,099	$27.56	$85,408.44	1,089,936
7/31/2024	Richard A Heyman	Director	Sell	1,702	$27.51	$46,822.02	131,643
7/31/2024	Samuel Kintz	CEO	Sell	2,270	$27.56	$62,561.20	1,061,255
7/29/2024	Benjamin Hohl	CFO	Sell	5,250	$26.68	$140,070.00
7/29/2024	Joseph P Lyssikatos	Insider	Sell	12,000	$26.70	$320,400.00	1,093,035
7/25/2024	Samuel Kintz	CEO	Sell	12,000	$24.92	$299,040.00	1,063,525
7/15/2024	Anish Patel	COO	Sell	30,978	$25.05	$775,998.90	345,574
7/15/2024	Richard A Heyman	Director	Sell	1,270	$24.80	$31,496.00	133,345
7/12/2024	Anish Patel	COO	Sell	17,475	$25.07	$438,098.25	376,552
7/12/2024	Benjamin Hohl	CFO	Sell	3,000	$25.07	$75,210.00
6/27/2024	Benjamin Hohl	CFO	Sell	4,250	$22.57	$95,922.50
6/25/2024	Samuel Kintz	CEO	Sell	12,000	$21.66	$259,920.00	1,075,525
6/6/2024	Anish Patel	COO	Sell	1,133	$20.06	$22,727.98
5/28/2024	Benjamin Hohl	CFO	Sell	4,250	$23.18	$98,515.00
5/28/2024	Samuel Kintz	CEO	Sell	12,000	$23.18	$278,160.00
5/16/2024	Rishi Gupta	Director	Sell	1,033,300	$22.14	$22,877,262.00	254,814
5/14/2024	Anish Patel	COO	Sell	1,107	$25.00	$27,675.00
5/9/2024	Anish Patel	COO	Sell	260	$25.06	$6,515.60
5/6/2024	Anish Patel	COO	Sell	4,875	$22.72	$110,760.00
5/3/2024	Benjamin Hohl	CFO	Sell	1,000	$22.50	$22,500.00
4/29/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
4/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$17.92	$215,040.00
4/25/2024	Samuel Kintz	CEO	Sell	12,000	$16.89	$202,680.00
4/15/2024	Richard A Heyman	Director	Sell	1,270	$19.99	$25,387.30	137,155
4/11/2024	Anish Patel	COO	Sell	17,500	$25.03	$438,025.00
4/11/2024	Benjamin Hohl	CFO	Sell	14,000	$24.72	$346,080.00
4/11/2024	Joseph P. Lyssikatos	insider	Sell	30,000	$25.04	$751,200.00
4/11/2024	Rahul D Ballal	Director	Sell	53,400	$23.95	$1,278,930.00	22,341
4/11/2024	Samuel Kintz	CEO	Sell	47,709	$25.04	$1,194,633.36
4/8/2024	Anish Patel	COO	Sell	4,875	$18.60	$90,675.00	2,597
4/4/2024	Rahul D Ballal	Director	Sell	3,485	$19.15	$66,737.75	22,341
4/1/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$18.60	$223,200.00
4/1/2024	Rahul D Ballal	Director	Sell	3,237	$19.08	$61,761.96	22,341
3/27/2024	Benjamin Hohl	CFO	Sell	3,250	$18.25	$59,312.50
3/25/2024	Samuel Kintz	CEO	Sell	12,000	$17.56	$210,720.00
3/19/2024	Richard A Heyman	Director	Sell	1,270	$14.50	$18,415.00	143,470
3/6/2024	Anish Patel	COO	Sell	4,875	$15.64	$76,245.00	7,472
2/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$16.42	$197,040.00
2/27/2024	Benjamin Hohl	CFO	Sell	3,250	$16.97	$55,152.50
2/15/2024	Richard A Heyman	Director	Sell	1,270	$17.42	$22,123.40	144,740
2/6/2024	Anish Patel	COO	Sell	4,875	$15.11	$73,661.25	12,347
1/31/2024	5Am Partners Vi, Llc	Major Shareholder	Sell	500,000	$15.00	$7,500,000.00	771,983
1/30/2024	Richard A Heyman	Director	Sell	1,270	$16.41	$20,840.70	146,010
1/29/2024	Benjamin Hohl	CFO	Sell	3,250	$15.81	$51,382.50
1/29/2024	Joseph P. Lyssikatos	insider	Sell	12,000	$15.85	$190,200.00
1/25/2024	Samuel Kintz	CEO	Sell	12,000	$15.69	$188,280.00
1/22/2024	Anish Patel	COO	Sell	4,875	$15.13	$73,758.75	17,222
1/2/2024	Anish Patel	COO	Sell	11,000	$15.00	$165,000.00	22,097
1/2/2024	Benjamin Hohl	CFO	Sell	9,383	$15.01	$140,838.83
12/26/2023	Anish Patel	COO	Sell	102	$15.01	$1,531.02	35,637
12/26/2023	Benjamin Hohl	CFO	Sell	100	$15.00	$1,500.00
12/26/2023	Samuel Kintz	CEO	Sell	12,000	$14.64	$175,680.00
12/22/2023	Anish Patel	COO	Sell	983	$15.03	$14,774.49	35,739
12/22/2023	Benjamin Hohl	CFO	Sell	1,030	$15.07	$15,522.10
12/22/2023	Samuel Kintz	CEO	Sell	8,175	$13.05	$106,683.75
12/21/2023	Joseph P. Lyssikatos	insider	Sell	20	$13.00	$260.00
12/21/2023	Richard A Heyman	Director	Sell	7	$13.00	$91.00	147,448
12/20/2023	Samuel Kintz	CEO	Sell	7,779	$13.01	$101,204.79
12/19/2023	Joseph P. Lyssikatos	insider	Sell	200	$13.00	$2,600.00
12/19/2023	Richard A Heyman	Director	Sell	255	$13.00	$3,315.00	149,565
11/3/2023	Joseph P. Lyssikatos	insider	Sell	8,546	$13.08	$111,781.68
11/3/2023	Samuel Kintz	CEO	Sell	8,026	$13.08	$104,980.08
9/29/2023	Joseph P. Lyssikatos	insider	Sell	12,000	$13.62	$163,440.00
9/26/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	197,500	$15.00	$2,962,500.00	854,796
9/25/2023	Samuel Kintz	CEO	Sell	12,000	$13.81	$165,720.00
8/24/2023	5Am Partners Vi, Llc	Major Shareholder	Sell	440,000	$16.00	$7,040,000.00	887,507

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Enliven Therapeutics (NASDAQ:ELVN)

95.08% of Enliven Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Enliven Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Patient Square Capital LP	90,572	$2.31M	0.9%	N/A	0.192%
11/15/2024	Ikarian Capital LLC	499,566	$12.76M	1.7%	-14.8%	1.058%
11/15/2024	Janus Henderson Group PLC	1,041,724	$26.61M	0.0%	+43.0%	2.205%
11/15/2024	HighVista Strategies LLC	112,459	$2.87M	1.0%	-6.1%	0.238%
11/14/2024	Verition Fund Management LLC	10,610	$0.27M	0.0%	N/A	0.022%
11/14/2024	Walleye Capital LLC	99,416	$2.54M	0.0%	N/A	0.210%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	26,168	$0.67M	0.0%	+12.7%	0.055%
11/14/2024	Ally Bridge Group NY LLC	234,856	$6M	3.2%	N/A	0.497%
11/14/2024	Acuta Capital Partners LLC	296,368	$7.57M	6.1%	-25.5%	0.627%
11/13/2024	FMR LLC	6,296,179	$160.80M	0.0%	+10.6%	13.328%
11/13/2024	The Manufacturers Life Insurance Company	17,282	$0.44M	0.0%	+25.6%	0.037%
11/12/2024	Charles Schwab Investment Management Inc.	255,277	$6.52M	0.0%	+10.4%	0.540%
11/7/2024	First Turn Management LLC	535,092	$13.67M	2.2%	+29.5%	1.133%
11/7/2024	Quest Partners LLC	21,117	$0.54M	0.0%	+1,226.4%	0.045%
10/25/2024	China Universal Asset Management Co. Ltd.	9,085	$0.23M	0.0%	+64.4%	0.019%
10/10/2024	Exchange Traded Concepts LLC	7,483	$0.19M	0.0%	-60.3%	0.016%
10/3/2024	SG Americas Securities LLC	10,013	$0.26M	0.0%	N/A	0.021%
8/15/2024	The Manufacturers Life Insurance Company	13,764	$0.32M	0.0%	N/A	0.029%
8/14/2024	Marshall Wace LLP	192,100	$4.49M	0.0%	N/A	0.408%
8/14/2024	Logos Global Management LP	595,000	$13.91M	1.1%	-62.2%	1.265%
8/14/2024	HighVista Strategies LLC	119,789	$2.80M	1.0%	-5.6%	0.255%
8/8/2024	First Turn Management LLC	413,243	$9.66M	1.6%	N/A	0.879%
8/8/2024	Nicholas Investment Partners LP	56,072	$1.31M	0.1%	N/A	0.119%
8/8/2024	American Century Companies Inc.	27,651	$0.65M	0.0%	+44.7%	0.059%
8/6/2024	Quest Partners LLC	1,592	$37K	0.0%	+87.3%	0.003%
8/1/2024	Rhumbline Advisers	49,627	$1.16M	0.0%	+29.9%	0.105%
7/26/2024	Bank of New York Mellon Corp	114,109	$2.67M	0.0%	+49.2%	0.243%
5/16/2024	California State Teachers Retirement System	19,141	$0.34M	0.0%	-5.8%	0.041%
5/16/2024	Janus Henderson Group PLC	713,911	$12.60M	0.0%	+74.8%	1.519%
5/16/2024	Blackstone Inc.	25,191	$0.44M	0.0%	N/A	0.054%
5/15/2024	Baker BROS. Advisors LP	114,833	$2.02M	0.0%	N/A	0.244%
5/14/2024	EntryPoint Capital LLC	9,510	$0.17M	0.1%	N/A	0.020%
5/10/2024	Vanguard Group Inc.	1,183,266	$20.81M	0.0%	-3.9%	2.517%
5/7/2024	SG Americas Securities LLC	9,430	$0.17M	0.0%	-30.2%	0.020%
4/29/2024	China Universal Asset Management Co. Ltd.	7,952	$0.14M	0.0%	+67.0%	0.017%
2/13/2024	Tower Research Capital LLC TRC	5,485	$76K	0.0%	-18.8%	0.013%
2/6/2024	AJOVista LLC	2,046	$28K	0.0%	N/A	0.005%
2/6/2024	Swiss National Bank	36,473	$0.51M	0.0%	-10.3%	0.089%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	12,305	$0.17M	0.0%	+9.1%	0.030%
1/24/2024	China Universal Asset Management Co. Ltd.	4,763	$66K	0.0%	N/A	0.012%
1/12/2024	SG Americas Securities LLC	13,501	$0.19M	0.0%	+17.8%	0.033%
1/5/2024	Exchange Traded Concepts LLC	8,708	$0.12M	0.0%	+34.0%	0.021%
12/6/2023	Citigroup Inc.	3,347	$46K	0.0%	-69.1%	0.008%
11/13/2023	FMR LLC	3,676,213	$50.22M	0.0%	-8.1%	8.923%
11/8/2023	Swiss National Bank	40,673	$0.56M	0.0%	-17.3%	0.099%
11/7/2023	Barclays PLC	13,629	$0.19M	0.0%	-8.1%	0.033%
10/23/2023	BML Capital Management LLC	50,000	$0.68M	0.6%	-32.6%	0.121%
10/13/2023	SG Americas Securities LLC	11,460	$0.16M	0.0%	N/A	0.028%
8/15/2023	HighVista Strategies LLC	121,073	$2.47M	1.1%	N/A	0.294%
8/15/2023	Commodore Capital LP	2,348,272	$47.93M	5.4%	+35.6%	5.707%
8/11/2023	VR Adviser LLC	2,230,127	$45.52M	7.3%	+0.7%	5.423%
8/10/2023	Metropolitan Life Insurance Co NY	1,279	$26K	0.0%	N/A	0.003%
8/4/2023	American International Group Inc.	11,235	$0.23M	0.0%	N/A	0.027%
8/3/2023	Bank of New York Mellon Corp	80,924	$1.65M	0.0%	+429.1%	0.197%
8/2/2023	Bank of Montreal Can	191,893	$3.95M	0.0%	N/A	0.467%
7/24/2023	BML Capital Management LLC	74,232	$1.52M	1.4%	-65.0%	0.181%
7/20/2023	Exchange Traded Concepts LLC	6,934	$0.14M	0.0%	N/A	0.017%
7/18/2023	Denali Advisors LLC	9,900	$0.20M	0.1%	N/A	0.024%
6/1/2023	Prelude Capital Management LLC	34,062	$40K	0.0%	N/A	0.519%
5/16/2023	Fairmount Funds Management LLC	1,924,938	$42.16M	7.2%	N/A	29.353%
5/16/2023	Boxer Capital LLC	710,644	$15.56M	0.8%	N/A	10.836%
5/15/2023	Commodore Capital LP	1,731,365	$37.92M	5.8%	N/A	26.401%
5/15/2023	Logos Global Management LP	401,229	$8.79M	1.3%	N/A	6.118%
5/12/2023	Mirabella Financial Services LLP	11,670	$0.26M	0.0%	N/A	0.178%
5/11/2023	FMR LLC	3,163,482	$69.28M	0.0%	N/A	48.239%
4/20/2023	Dorsey Wright & Associates	1,237	$27K	0.0%	N/A	0.019%

Data available starting January 2016

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $24.41

$23.70

$25.00

50 Day Range

MA: $26.22

$21.44

$29.55

52 Week Range

Now: $24.41

$9.80

$30.03

Volume

248,450 shs

Average Volume

260,255 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Who are the company insiders with the largest holdings of Enliven Therapeutics?: Enliven Therapeutics' top insider investors include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Joseph P Lyssikatos (Insider)
Learn More about top insider investors at Enliven Therapeutics.
Who are the major institutional investors of Enliven Therapeutics?: Enliven Therapeutics' top institutional shareholders include:
FMR LLC — 13.33%
RA Capital Management L.P. — 2.25%
Janus Henderson Group PLC — 2.21%
State Street Corp — 1.58%
First Turn Management LLC — 1.13%
Ikarian Capital LLC — 1.06%
Learn More about top institutional investors of Enliven Therapeutics stock.
Which institutional investors are selling Enliven Therapeutics stock?: Within the previous quarter, ELVN stock was sold by these institutional investors:
RA Capital Management L.P.
Acuta Capital Partners LLC
Ikarian Capital LLC
Jane Street Group LLC
Exchange Traded Concepts LLC
HighVista Strategies LLC
In the previous year, company insiders that have sold Enliven Therapeutics company stock include:
Joseph P Lyssikatos (Insider)
Samuel Kintz (CEO)
5Am Partners Vi, Llc (Major Shareholder)
Anish Patel (COO)
Rishi Gupta (Director)
Richard A Heyman (Director)
Rahul D Ballal (Director)
Benjamin Hohl (CFO)
Joseph P Lyssikatos (Insider)
Learn More investors selling Enliven Therapeutics stock.
Which institutional investors are buying Enliven Therapeutics stock?: During the previous quarter, ELVN stock was acquired by institutional investors including:
FMR LLC
Janus Henderson Group PLC
Ally Bridge Group NY LLC
First Turn Management LLC
Walleye Capital LLC
Patient Square Capital LP
Wellington Management Group LLP
Charles Schwab Investment Management Inc.